联合疗法-话题@MedSci

#联合疗法#

64篇内容 | 2888人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2246743, encodeId=01c02246e43d2, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Nat Genet：张鹏/王晨飞/孙毅/张乐乐/曾安团队合作利用多组学分析揭示NSCLC免疫联合化疗的耐药因素, objectType=article, longId=856806, objectId=cc0b8568063a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721377358220_92910.png, objectUrl=/article/show_article.do?id=cc0b8568063a, replyNumber=0, likeNumber=25, createdTime=2025-01-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=cc0b8568063a, moduleTitle=Nat Genet：张鹏/王晨飞/孙毅/张乐乐/曾安团队合作利用多组学分析揭示NSCLC免疫联合化疗的耐药因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc0b8568063a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216490, encodeId=9043221649087, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=e6dd29094a1' target=_blank style='color:#2F92EE;'>#免疫疗法#</a>, objectTitle=ADC的联合治疗之路, objectType=article, longId=835251, objectId=0dbd8352513c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721377067764_92910.png, objectUrl=/article/show_article.do?id=0dbd8352513c, replyNumber=0, likeNumber=0, createdTime=2024-07-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0dbd8352513c, moduleTitle=ADC的联合治疗之路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dbd8352513c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2215213, encodeId=3d51221521308, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a> <a href='/topic/show?id=0472116e390d' target=_blank style='color:#2F92EE;'>#肠杆菌科细菌#</a>, objectTitle=重磅更新：IDSA 2024 年抗菌药物耐药性革兰氏阴性菌感染治疗指南, objectType=article, longId=834664, objectId=646b83466494, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720699151201_8538692.png, objectUrl=/article/show_article.do?id=646b83466494, replyNumber=0, likeNumber=101, createdTime=2024-07-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=646b83466494, moduleTitle=重磅更新：IDSA 2024 年抗菌药物耐药性革兰氏阴性菌感染治疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=646b83466494)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1647013, encodeId=af74164e0132e, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Nature子刊：陈列平教授思考PD-1联合疗法临床试验, objectType=article, longId=729999, objectId=cfe5e2999992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfe5e2999992, replyNumber=0, likeNumber=96, createdTime=2022-09-09, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfe5e2999992, moduleTitle=Nature子刊：陈列平教授思考PD-1联合疗法临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfe5e2999992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647010, encodeId=30b8164e010f8, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Carbohydr Polym：化疗-光动力联合疗法治疗银屑病：壳聚糖/透明质酸纳米凝胶共传递甲氨蝶呤和5-氨基乙酰丙酸, objectType=article, longId=293130, objectId=6f36293130d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f36293130d3, replyNumber=0, likeNumber=130, createdTime=2022-08-22, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f36293130d3, moduleTitle=Carbohydr Polym：化疗-光动力联合疗法治疗银屑病：壳聚糖/透明质酸纳米凝胶共传递甲氨蝶呤和5-氨基乙酰丙酸, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f36293130d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647012, encodeId=84ba164e012c9, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Nat Med：胰腺癌免疫联合疗法，一年生存率增加近65%！, objectType=article, longId=729392, objectId=cb2ee293927d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2ee293927d, replyNumber=0, likeNumber=105, createdTime=2023-02-04, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2ee293927d, moduleTitle=Nat Med：胰腺癌免疫联合疗法，一年生存率增加近65%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2ee293927d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647008, encodeId=7c14164e0088f, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=新冠特效药来了！我国新冠中和抗体联合疗法获批, objectType=article, longId=221785, objectId=898a221e855c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898a221e855c, replyNumber=0, likeNumber=84, createdTime=2022-01-04, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898a221e855c, moduleTitle=新冠特效药来了！我国新冠中和抗体联合疗法获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898a221e855c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647006, encodeId=e157164e00617, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=AJRCCM：肺动脉高压联合疗法、分阶段及目标导向疗法, objectType=article, longId=218631, objectId=0cea218631ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cea218631ef, replyNumber=0, likeNumber=89, createdTime=2022-07-25, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cea218631ef, moduleTitle=AJRCCM：肺动脉高压联合疗法、分阶段及目标导向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cea218631ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647011, encodeId=8275164e0110e, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, objectType=article, longId=300740, objectId=1daa300e408c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1daa300e408c, replyNumber=0, likeNumber=101, createdTime=2022-10-16, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1daa300e408c, moduleTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1daa300e408c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647005, encodeId=b10d164e005ab, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=腾盛博药单克隆抗体联合疗法使住院和死亡复合终点降低78%, objectType=article, longId=216340, objectId=d3282163405f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3282163405f, replyNumber=0, likeNumber=103, createdTime=2022-04-07, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3282163405f, moduleTitle=腾盛博药单克隆抗体联合疗法使住院和死亡复合终点降低78%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3282163405f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647007, encodeId=5b81164e00755, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, objectType=article, longId=218973, objectId=dbd52189e3d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd52189e3d5, replyNumber=0, likeNumber=92, createdTime=2022-05-18, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd52189e3d5, moduleTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd52189e3d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647009, encodeId=8df0164e00943, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, objectType=article, longId=293031, objectId=0376293031b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0376293031b8, replyNumber=0, likeNumber=80, createdTime=2022-01-03, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0376293031b8, moduleTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0376293031b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647000, encodeId=9107164e00034, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Nature Communications：瑞德西韦联合疗法可治疗晚期马尔堡病毒病, objectType=article, longId=209080, objectId=b3c4209080d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c4209080d8, replyNumber=0, likeNumber=85, createdTime=2021-08-04, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c4209080d8, moduleTitle=Nature Communications：瑞德西韦联合疗法可治疗晚期马尔堡病毒病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3c4209080d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646999, encodeId=17ae164699971, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, objectType=article, longId=207256, objectId=1d0f20e25662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0f20e25662, replyNumber=0, likeNumber=74, createdTime=2021-12-11, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0f20e25662, moduleTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0f20e25662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, objectType=article, longId=209545, objectId=c8ee20954549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ee20954549, replyNumber=0, likeNumber=107, createdTime=2021-09-17, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ee20954549, moduleTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ee20954549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647002, encodeId=510a164e00288, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, objectType=article, longId=210997, objectId=424321099e06, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=424321099e06, replyNumber=0, likeNumber=89, createdTime=2021-12-26, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=424321099e06, moduleTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=424321099e06)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647004, encodeId=77d6164e00417, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后, objectType=article, longId=213719, objectId=ff64213e19af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff64213e19af, replyNumber=0, likeNumber=106, createdTime=2022-03-07, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff64213e19af, moduleTitle=NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff64213e19af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647003, encodeId=61b1164e00344, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Science Tranlational Medicine：为肿瘤免疫疗法“保驾护航”，中美科学家发布全新癌症阻断联合疗法！, objectType=article, longId=213643, objectId=82402136432c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82402136432c, replyNumber=0, likeNumber=125, createdTime=2021-10-14, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82402136432c, moduleTitle=Science Tranlational Medicine：为肿瘤免疫疗法“保驾护航”，中美科学家发布全新癌症阻断联合疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82402136432c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646995, encodeId=bf571646995bd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌, objectType=article, longId=203136, objectId=a3c920313621, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c920313621, replyNumber=0, likeNumber=99, createdTime=2021-09-08, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c920313621, moduleTitle=IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3c920313621)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646998, encodeId=947f16469986c, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, objectType=article, longId=207255, objectId=f8f020e25546, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f020e25546, replyNumber=0, likeNumber=127, createdTime=2021-03-15, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f020e25546, moduleTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8f020e25546)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合疗法

2020-05-29

梅斯管理员

#NSCLC# #联合疗法#

Nat Genet：张鹏/王晨飞/孙毅/张乐乐/曾安团队合作利用多组学分析揭示NSCLC免疫联合化疗的耐药因素

2025-01-05发表于陕西省

梅斯管理员

#联合疗法# #抗体偶联药物# #免疫疗法#

ADC的联合治疗之路

2024-07-23发表于上海

梅斯管理员

#联合疗法# #肠杆菌科细菌#

重磅更新：IDSA 2024 年抗菌药物耐药性革兰氏阴性菌感染治疗指南

2024-07-16发表于上海

wincls

#联合疗法#

Nature子刊：陈列平教授思考PD-1联合疗法临床试验

2022-09-09

wincls

#联合疗法#

Carbohydr Polym：化疗-光动力联合疗法治疗银屑病：壳聚糖/透明质酸纳米凝胶共传递甲氨蝶呤和5-氨基乙酰丙酸

2022-08-22

wincls

#联合疗法#

Nat Med：胰腺癌免疫联合疗法，一年生存率增加近65%！

2023-02-04

wincls

#联合疗法#

新冠特效药来了！我国新冠中和抗体联合疗法获批

2022-01-04

wincls

#联合疗法#

AJRCCM：肺动脉高压联合疗法、分阶段及目标导向疗法

2022-07-25

wincls

#联合疗法#

默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌

2022-10-16

wincls

#联合疗法#

腾盛博药单克隆抗体联合疗法使住院和死亡复合终点降低78%

2022-04-07

wincls

#联合疗法#

JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者

2022-05-18

wincls

#联合疗法#

NEJM：Relugolix联合疗法治疗子宫肌瘤

2022-01-03

wincls

#联合疗法#

Nature Communications：瑞德西韦联合疗法可治疗晚期马尔堡病毒病

2021-08-04

wincls

#联合疗法#

NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验

2021-12-11

wincls

#联合疗法#

默沙东联合Surface开展联合疗法研究，或将改善K药耐药性

2021-09-17

wincls

#联合疗法#

Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后

2021-12-26

wincls

#联合疗法#

NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后

2022-03-07

wincls

#联合疗法#

Science Tranlational Medicine：为肿瘤免疫疗法“保驾护航”，中美科学家发布全新癌症阻断联合疗法！

2021-10-14

wincls

#联合疗法#

IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌

2021-09-08

wincls

#联合疗法#

NEJM：Relugolix联合疗法治疗子宫肌瘤

2021-03-15